Best Peptides for Skin & Hair: What Works

Skin and hair share more biology than most people realize. Both depend on the same dermal structures — fibroblasts that produce collagen, follicular stem cells that cycle through growth phases, and signaling pathways like Wnt/beta-catenin that determine whether tissue regenerates or degrades. When these systems slow down with age, you get thinner skin and thinner hair at the same time, for the same underlying reasons.

This overlap is why certain peptides show up in both skin rejuvenation and hair regrowth research. GHK-Cu was studied for decades as a wound-healing compound before researchers noticed it also influenced hair follicle gene expression. PTD-DBM was designed to reactivate a specific hair growth pathway, but the same Wnt signaling it targets also drives skin repair. The melanocortins — melanotan-1 and melanotan-2 — primarily modify skin pigmentation, but their receptor system touches photoprotection, DNA repair, and immune modulation in ways that go well beyond cosmetic tanning.

This guide covers the five peptides with the strongest evidence for skin quality, hair growth, or both. Each section breaks down the mechanism, the actual research, and practical guidance for use.

Skin and Hair Peptide Comparison

GHK-Cu: The Collagen Architect

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma, saliva, and urine. Plasma levels average around 200 ng/mL at age 20 and decline to approximately 80 ng/mL by age 60 — a 60% reduction that tracks closely with visible skin aging. This age-related decline is not coincidental. GHK-Cu is one of the body's primary signals for tissue remodeling, and as its concentration drops, so does the skin's capacity to repair and regenerate.

The scope of GHK-Cu's biological activity is unusually broad. Gene expression studies using the Broad Institute's Connectivity Map identified over 4,000 human genes modulated by GHK — roughly 6% of the human genome. These genes cluster in tissue remodeling, antioxidant defense, and anti-inflammatory pathways (PMID:29986520). This is not a peptide that targets one receptor or one enzyme. It operates as a systemic reset signal for tissue maintenance programs that decline with age.

For skin specifically, GHK-Cu stimulates fibroblast production of type I and type III collagen, elastin, and glycosaminoglycans — the three structural components whose loss produces wrinkles, sagging, and thinning skin. The original fibroblast culture studies demonstrated significant collagen synthesis increases at concentrations achievable through both topical and injectable delivery (PMID:3169264). The copper ion is not incidental — it serves as a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into mechanically strong fibers. Without adequate copper delivery to the dermis, newly synthesized collagen forms weak, disorganized structures rather than the organized matrix that gives young skin its firmness.

Beyond structural proteins, GHK-Cu acts as a remodeling coordinator. It increases synthesis of metalloproteinases (MMPs) that break down damaged collagen while simultaneously stimulating production of new collagen to replace it. This dual action — controlled degradation plus accelerated synthesis — explains why GHK-Cu improves scar tissue, not just healthy skin. Scar tissue is primarily composed of disorganized type I collagen deposited rapidly during wound closure. GHK-Cu promotes the gradual replacement of this disorganized matrix with properly structured tissue, which is why dermatologists have explored it for post-surgical scar reduction and stretch mark improvement.

The hair follicle connection runs through the same tissue remodeling pathways. Hair follicles are surrounded by a dermal sheath composed of collagen and extracellular matrix — the structural environment that supports the follicle through its growth cycle. GHK-Cu's stimulation of the extracellular matrix extends to this perifollicular tissue, creating a more supportive environment for follicle cycling. Additionally, GHK-Cu upregulates genes involved in dermal papilla cell function, and the dermal papilla is the signaling center that determines whether a hair follicle enters its growth phase (anagen) or regression phase (catagen). The peptide also suppresses TGF-beta, which is elevated in balding scalp tissue and contributes to follicle miniaturization.

Practical guidance: For skin rejuvenation, topical GHK-Cu at 1-2% concentration applied to clean skin delivers the peptide directly to dermal fibroblasts. Twice-daily application is standard, with visible texture and tone improvements typically emerging at 4-8 weeks. For deeper tissue effects or hair follicle support, subcutaneous injection at 1-2mg daily provides systemic delivery. Injectable GHK-Cu can be combined with microneedling for enhanced scalp penetration in hair loss applications. For full protocols, see the GHK-Cu Dosing Guide.

Melanotan-1: The Photoprotector

Melanotan-1 (afamelanotide, [Nle4, D-Phe7]-alpha-MSH) is a synthetic analog of alpha-melanocyte-stimulating hormone that selectively activates the melanocortin 1 receptor (MC1R). Its primary effect is stimulating melanocytes to produce eumelanin — the dark, photoprotective pigment that absorbs UV radiation and neutralizes free radicals in the skin. Unlike cosmetic tanning, which primarily involves oxidation of existing melanin, melanotan-1 drives genuine de novo eumelanin synthesis that provides measurable DNA protection.

The clinical development path for melanotan-1 is unusual among peptides in this guide because it reached FDA approval. Afamelanotide (marketed as Scenesse) was approved for erythropoietic protoporphyria (EPP), a condition where patients cannot tolerate any sunlight. In EPP trials, afamelanotide implants increased pain-free time in sunlight by a clinically significant margin, demonstrating that the eumelanin produced was functionally photoprotective — not merely cosmetic (PMID:21073357).

For individuals without EPP, the photoprotection mechanism is equally relevant. MC1R activation by melanotan-1 does more than produce pigment — it upregulates DNA repair enzymes in melanocytes and keratinocytes, enhancing the skin's ability to fix UV-induced pyrimidine dimers (the DNA lesions that initiate skin cancer). In human volunteers, melanotan-1 combined with UV exposure produced significantly greater tanning responses than UV alone, and this tanning persisted longer because it was driven by new melanin synthesis rather than redistribution of existing pigment.

The MC1R selectivity of melanotan-1 matters because it explains the relatively clean side-effect profile. MC1R is expressed predominantly on melanocytes and some immune cells. Melanotan-1 does not significantly activate MC3R (metabolic regulation), MC4R (appetite and sexual function), or MC5R (exocrine glands) at standard doses. This receptor selectivity means melanotan-1 produces pigmentation without the nausea, appetite suppression, or sexual side effects that characterize less selective melanocortin agonists.

A particularly compelling application is in individuals with MC1R loss-of-function variants — the genetic basis for red hair and fair skin. These individuals produce predominantly pheomelanin (the red/yellow pigment that offers minimal UV protection and may generate free radicals upon UV exposure) rather than eumelanin. Studies demonstrated that melanotan-1 can shift pigment production toward eumelanin even in MC1R variant carriers, potentially offering photoprotection to the population most vulnerable to UV-induced skin damage.

Practical guidance: The FDA-approved delivery is a subcutaneous implant (16mg, releasing over 60 days), but research-grade melanotan-1 is available as an injectable peptide. Typical protocols use 250mcg subcutaneously 2-3 times per week during UV exposure seasons. Gradual pigmentation develops over 2-4 weeks. For full protocols, see the Melanotan-1 Dosing Guide. For a detailed comparison with melanotan-2, see Melanotan 1 vs 2: Safety vs Potency.

Melanotan-2: Tanning with Trade-offs

Melanotan-2 is a cyclic heptapeptide analog of alpha-MSH that activates melanocortin receptors non-selectively — hitting MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function and appetite), and MC5R (exocrine secretion). This broad receptor profile makes it more potent for tanning than melanotan-1, but also introduces a side-effect profile that extends well beyond the skin.

The tanning effect is real and well-documented. In the original Phase I clinical trial, subjects receiving just five low-dose subcutaneous injections of melanotan-2 on alternating days developed measurable increases in skin pigmentation across the face, trunk, and extremities. Quantitative reflectance measurements confirmed increased melanin density, and the pigmentation persisted for weeks after dosing ended (PMID:8637402). The mechanism is the same MC1R-driven eumelanin synthesis as melanotan-1, but the cyclic peptide structure of melanotan-2 increases receptor binding affinity and extends biological half-life compared to the linear melanotan-1 molecule.

The problem is everything else melanotan-2 does. MC4R activation in the hypothalamus produces appetite suppression, which some users view as a benefit but which can be significant enough to interfere with caloric intake during training or recovery periods. The same MC4R activation drives sexual arousal effects — spontaneous erections in men, increased libido in both sexes — which led to the development of PT-141 (bremelanotide), a melanocortin derivative specifically optimized for this application. Nausea is common during the loading phase, particularly at higher doses or with rapid titration. Facial flushing occurs in a majority of users and can persist for 1-2 hours post-injection.

The melanoma question requires direct attention. Case reports have documented new nevi (moles) appearing during melanotan-2 use, changes in existing moles, and in rare instances, melanoma diagnosis in melanotan-2 users. The relationship between melanotan-2 and melanoma is not definitively causal — melanoma has a long latency period and many confounders — but the concern is biologically plausible. MC1R stimulation drives melanocyte proliferation alongside melanin production. In individuals with pre-existing atypical nevi or genetic melanoma risk factors, stimulating melanocyte growth could theoretically accelerate transformation. This is why dermatological monitoring is non-negotiable during melanotan-2 use: baseline mole mapping and regular skin checks every 3-6 months.

Practical guidance: Melanotan-2 is used at 250-500mcg subcutaneously during loading (daily or every other day for 2-3 weeks), then 1-2 times per week for maintenance. Start at the lower end to assess nausea tolerance. Anti-nausea measures (dosing before bed, taking with food) help during loading. If your primary goal is photoprotection without the side-effect profile, melanotan-1 is the better choice. For detailed protocols and side-effect management, see the Melanotan-2 Dosing Guide and Melanotan-2 Side Effects. For the sexual function crossover with PT-141, see PT-141 vs Melanotan 2.

PTD-DBM: The Hair Regrowth Signal

PTD-DBM (protein transduction domain-Dishevelled binding motif) represents a fundamentally different approach to hair loss than hormonal interventions like finasteride or minoxidil. Rather than blocking DHT or increasing blood flow to the scalp, PTD-DBM directly reactivates the Wnt/beta-catenin signaling pathway — the master regulator of hair follicle stem cell activation and the signal that determines whether miniaturized follicles re-enter the growth phase.

The target is CXXC5 (CXXC-type zinc finger protein 5), a negative feedback regulator that suppresses Wnt/beta-catenin signaling by binding to Dishevelled (Dvl), a key intracellular signal transducer. In balding scalp tissue, CXXC5 expression is elevated, which dampens the Wnt signal that would otherwise activate hair follicle stem cells and push dormant follicles into anagen (the growth phase). PTD-DBM is a competing peptide that disrupts the CXXC5-Dvl interaction, effectively removing the brake on Wnt signaling and allowing the pathway to reactivate.

The foundational study from the Yonsei University group demonstrated this mechanism across multiple models. CXXC5 knockout mice displayed accelerated hair regrowth compared to wild-type controls. Treatment with PTD-DBM replicated this effect in normal mice — stimulating both hair regrowth in shaved models and wound-induced hair follicle neogenesis (the generation of entirely new hair follicles in wound margins). The wound-induced neogenesis finding is particularly significant because it suggests PTD-DBM does not merely reactivate existing follicles but may support the formation of new ones (PMID:28595998).

The DHT connection adds clinical relevance for androgenetic alopecia specifically. Subsequent research from the same group showed that CXXC5 mediates DHT-induced hair loss through prostaglandin D2 (PGD2) — a lipid mediator elevated in balding scalp tissue. DHT upregulates CXXC5, which suppresses Wnt signaling, which leads to follicle miniaturization. PTD-DBM treatment restored hair growth in DHT-exposed models and overcame PGD2-mediated suppression of wound-induced hair neogenesis (PMID:36831222). This positions PTD-DBM as a mechanistically complementary approach to finasteride — finasteride reduces DHT production upstream, while PTD-DBM counteracts one of DHT's downstream effects on follicle signaling.

The distinction between PTD-DBM and conventional hair loss treatments matters for treatment selection. Minoxidil works primarily through vasodilation and potassium channel opening — increasing blood flow to the scalp. Finasteride blocks 5-alpha-reductase to reduce DHT levels systemically. Neither directly addresses the Wnt signaling deficit that characterizes miniaturized follicles. PTD-DBM targets this deficit directly, which is why early research suggests it may help non-responders to conventional treatments. The limitation is that human clinical data remains at the preclinical stage — the mouse and cell culture results are compelling, but controlled human trials have not yet been published.

Practical guidance: PTD-DBM is typically applied topically to the scalp at concentrations of 1-5mM in research protocols. Topical delivery via microneedling (0.5-1.0mm dermaroller) enhances penetration through the stratum corneum to reach the dermal papilla. Application 2-3 times per week after microneedling is a common research protocol. Expect a minimum 3-6 month timeline before evaluating results — hair follicle cycling is inherently slow, and one full anagen cycle must complete before new growth becomes visible.

Thymulin: The Zinc-Dependent Hair Regulator

Thymulin is a nonapeptide hormone produced by thymic epithelial cells, consisting of nine amino acids (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) with an absolute requirement for zinc binding to achieve biological activity. The zinc ion must be present in an equimolar ratio — without it, thymulin cannot bind its receptor and is functionally inert (PMID:2657247). This zinc dependency creates an important practical consideration: thymulin supplementation is ineffective in zinc-deficient individuals, and subclinical zinc deficiency is remarkably common (estimated 15-20% of the global population).

Thymulin's connection to hair growth was established through organ culture studies using human hair follicles. Research demonstrated that thymic peptides, including thymulin, modulate human hair follicle growth directly — not through systemic immune effects, but through local signaling at the follicle level (PMID:22402437). This local action distinguishes thymulin from its better-known immune functions (T-cell maturation, immune surveillance) and positions it as a follicular growth modulator with a dual mechanism.

The immune connection matters specifically for alopecia areata — the autoimmune form of hair loss where the immune system attacks hair follicles. Thymulin's immunomodulatory properties help restore immune tolerance to follicular tissue while its direct follicular effects support regrowth once the autoimmune attack subsides. This dual action makes thymulin mechanistically suited to immune-mediated hair loss in ways that purely growth-signaling peptides like PTD-DBM are not. For androgenetic alopecia (pattern baldness), thymulin's evidence is weaker — the hair loss mechanism is hormonal rather than immunological, and thymulin's influence on DHT-driven miniaturization is less established.

The zinc-thymulin axis also connects to a broader pattern in hair loss. Serum zinc levels correlate with serum thymulin activity, and zinc deficiency independently causes diffuse hair shedding (telogen effluvium). When thymulin levels decline — either through aging (thymic involution reduces thymulin output significantly after age 40) or through zinc depletion — hair follicles lose a regulatory signal that supports their growth cycle. Supplementing thymulin alongside adequate zinc may restore this signal in individuals whose hair loss has an immune or nutritional component.

Practical guidance: Thymulin is administered subcutaneously at 100-500mcg, typically 2-3 times per week. Zinc co-supplementation at 15-30mg daily (as zinc picolinate or bisglycinate for superior absorption) is mandatory — not optional. Check serum zinc at baseline to establish whether deficiency is contributing to hair loss independently. For immune-mediated hair loss (alopecia areata), thymulin is often combined with other immunomodulatory approaches. For full protocols, see the Thymulin Dosing Guide.

Stacking Recommendations

Skin and hair peptides can be combined effectively because they operate through distinct mechanisms. The key principle is the same as with healing peptides: stack compounds that complement each other's pathways rather than duplicating them.

Skin rejuvenation stack — GHK-Cu + Melanotan-1: GHK-Cu rebuilds the structural matrix (collagen, elastin, GAGs) while melanotan-1 strengthens the skin's UV defense system through eumelanin production. Together, they address the two primary drivers of skin aging — structural degradation and UV damage accumulation. Apply GHK-Cu topically twice daily, administer melanotan-1 subcutaneously 2-3 times per week. This combination is particularly relevant for individuals with fair skin who want both rejuvenation and photoprotection.

Hair regrowth stack — PTD-DBM + GHK-Cu + Zinc: PTD-DBM reactivates Wnt/beta-catenin signaling to push dormant follicles into anagen. GHK-Cu supports the perifollicular extracellular matrix and suppresses TGF-beta. Zinc ensures adequate cofactor availability for follicular enzyme systems and thymulin activity. Apply PTD-DBM topically after microneedling 2-3 times per week. Apply GHK-Cu topically to the scalp on alternate days. Supplement zinc at 15-30mg daily orally.

Immune-mediated hair loss stack — Thymulin + GHK-Cu + Zinc: For alopecia areata specifically, thymulin addresses the autoimmune component while GHK-Cu supports follicular recovery once immune attack subsides. Zinc is mandatory for thymulin activity. This stack targets the root cause (immune dysregulation) and the downstream effect (follicular damage) simultaneously.

What NOT to stack: Melanotan-1 and melanotan-2 should not be combined — they compete for the same MC1R receptor, and adding melanotan-2's non-selective receptor activation to melanotan-1's selective action gains nothing while adding side effects. Choose one or the other based on your risk tolerance and goals.

How to Choose: Skin vs Hair

The decision framework depends on whether your primary goal is skin quality, hair growth, or both — and on the specific type of skin or hair concern.

If your goal is skin rejuvenation (wrinkles, texture, firmness): GHK-Cu is the clear first choice. No other peptide in this category has the same depth of evidence for collagen synthesis, elastin production, and extracellular matrix remodeling. Start with topical GHK-Cu at 1-2% concentration for 8-12 weeks. If you want to accelerate results, add subcutaneous injection at 1-2mg daily. Expect visible texture improvement at 4-8 weeks, with continued gains through 12-16 weeks.

If your goal is UV protection and skin cancer risk reduction: Melanotan-1 is the evidence-based choice — it has FDA approval (for EPP), clinical trial data in multiple skin conditions, and a selective mechanism that minimizes off-target effects. Melanotan-2 produces darker tanning faster but carries a higher side-effect burden and unresolved melanoma safety questions. Use melanotan-1 unless you specifically want the more aggressive tanning response and accept the trade-offs.

If your goal is androgenetic alopecia (male or female pattern hair loss): PTD-DBM addresses the Wnt signaling deficit that characterizes follicle miniaturization. It is mechanistically complementary to finasteride (DHT reduction) and minoxidil (vasodilation), so it can be added to existing protocols rather than replacing them. Combine with GHK-Cu for follicular matrix support. Timeline: 3-6 months minimum.

If your goal is immune-mediated hair loss (alopecia areata): Thymulin is the targeted choice because it addresses both the immunological cause (autoimmune follicular attack) and the growth signal (direct follicular modulation). Ensure zinc status is optimized. This is the one scenario where thymulin has a clear advantage over PTD-DBM.

If your goal is both skin and hair: GHK-Cu is the foundation for any combined protocol. It is the only peptide with strong evidence across both applications. Add PTD-DBM for hair-specific Wnt activation if androgenetic alopecia is the hair concern, or thymulin + zinc if the hair loss is immune-mediated. Add melanotan-1 if UV protection is also a priority.

Monitoring and Bloodwork

Skin and hair peptides work on slower timelines than healing or performance peptides, which makes objective monitoring more important — you need data to confirm something is happening before visible changes appear.

Baseline labs before starting any protocol: Serum zinc is essential before using thymulin and is informative for any hair loss protocol — zinc deficiency independently causes telogen effluvium and will undermine any peptide intervention. Check a complete metabolic panel (CMP) for liver enzymes (ALT, AST) and kidney function (BUN, creatinine) as a safety baseline. For melanotan protocols, get a baseline dermatological skin check with mole mapping — you need documented baseline mole status before introducing any melanocyte-stimulating compound.

Hormone panel for hair loss protocols: If hair loss is a primary concern, a hormone panel adds essential context. Free and total testosterone, DHT, DHEA-S, and thyroid panel (TSH, free T3, free T4) identify hormonal contributors that peptides alone cannot address. In women, checking estradiol and progesterone adds information about hormonal hair loss patterns. Elevated DHT with low SHBG is a common finding in androgenetic alopecia that may warrant concurrent finasteride or dutasteride. Iron studies (ferritin, serum iron, TIBC) are particularly relevant for women with hair loss — ferritin below 40 ng/mL correlates with increased shedding even when hemoglobin appears normal.

Follow-up monitoring at 8-12 weeks: Repeat CMP to verify organ function during extended peptide use. Repeat zinc if using thymulin or zinc supplementation — zinc levels can overshoot with supplementation, and excess zinc depletes copper (which would counteract GHK-Cu protocols). For melanotan users, repeat dermatological skin check — any new or changing moles require evaluation regardless of whether melanotan is the cause.

Tracking skin outcomes objectively: Standardized photography under consistent lighting at baseline, 4 weeks, 8 weeks, and 12 weeks provides more reliable assessment than subjective perception. Photograph the same areas (under-eye, nasolabial folds, forehead, back of hands) at the same distance, angle, and lighting. Some users track skin hydration and elasticity with consumer-grade skin analyzers, though the accuracy of these devices varies.

Tracking hair outcomes objectively: Global photography of the scalp (vertex, frontal hairline, temporal regions) at baseline and monthly intervals captures changes that daily observation misses. Trichoscopy (dermoscopic evaluation of the scalp) provides more granular data — hair density per square centimeter, vellus-to-terminal hair ratio, and follicular unit counts. If your dermatologist offers trichoscopy, baseline and 3-month follow-up measurements provide the most objective assessment of whether a hair protocol is working.

FAQ

Can GHK-Cu improve both skin and hair simultaneously? Yes. GHK-Cu modulates over 4,000 human genes involved in tissue remodeling, and its effects extend to both dermal fibroblasts (skin) and dermal papilla cells (hair follicles). Topical application targets skin directly, while subcutaneous injection provides broader systemic delivery that reaches follicular tissue. It is the only peptide in this category with strong evidence for both applications.

Is melanotan-2 safe for skin tanning? Melanotan-2 does produce visible tanning, but it carries more side effects than melanotan-1 — including nausea, facial flushing, and spontaneous erections. More concerning, case reports have linked melanotan-2 to changes in existing moles and, in rare cases, melanoma development. Melanotan-1 (afamelanotide) is the FDA-approved alternative with a cleaner safety profile for photoprotection.

How long before I see results from hair growth peptides? Hair follicle cycling is slow. PTD-DBM and thymulin typically require 3-6 months of consistent use before visible changes in hair density or thickness appear. Early signs — reduced shedding, finer vellus hair at the hairline — may emerge at 6-8 weeks. Skin peptides like GHK-Cu work faster, with texture and tone improvements often noticeable within 4-8 weeks.

Do I need to take zinc with thymulin? Yes. Thymulin is biologically inactive without zinc — the metal ion is required in an equimolar ratio for the peptide to bind its receptor. Supplementing with 15-30mg of zinc picolinate or zinc bisglycinate daily ensures adequate zinc availability. Check serum zinc levels at baseline, as many adults are mildly zinc-deficient without knowing it.

Can I use PTD-DBM and finasteride together? They work through entirely different mechanisms — PTD-DBM activates the Wnt/beta-catenin pathway while finasteride blocks DHT conversion. The combination is mechanistically complementary and there are no known interactions. PTD-DBM may be particularly useful for individuals who respond poorly to finasteride alone, as it addresses hair follicle stem cell activation rather than hormonal suppression.

Related Reading

• GHK-Cu Dosing Guide: Topical and Injectable
• GHK-Cu Bloodwork: 5 Labs to Track
• Melanotan-1 Dosing: 250mcg 2x/Week Protocol
• Melanotan 1 vs 2: Safety vs Potency
• Why Melanotan-1 May Be the Best Peptide
• Melanotan-2 Side Effects: 8 to Watch For
• PT-141 vs Melanotan 2: Key Differences
• Thymulin Benefits: 7 Immune Effects
• Thymulin Dosing: 100-500mcg + Zinc
• 7 Best Peptides for Anti-Aging, Ranked
• 4 Best Peptides for Healing and Recovery

References

1. Pickart L, et al. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PMID:29986520

2. Maquart FX, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. PMID:3169264

3. Harms J, et al. (2010). Afamelanotide, an agonistic analog of alpha-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. N Engl J Med. PMID:21073357

4. Dorr RT, et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. PMID:8637402

5. Lee SH, et al. (2017). Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. PMID:28595998

6. Lee SH, et al. (2023). CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. J Invest Dermatol. PMID:36831222

7. Meier N, et al. (2012). Thymic peptides differentially modulate human hair follicle growth. J Invest Dermatol. PMID:22402437

8. Dardenne M, et al. (1989). Thymulin, a zinc-dependent hormone. Med Oncol Tumor Pharmacother. PMID:2657247